Literature DB >> 9701243

The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas.

Y Kimura1, H Koga, N Araki, N Mugita, N Fujita, H Takeshima, T Nishi, T Yamashima, T C Saido, T Yamasaki, K Moritake, H Saya, M Nakao.   

Abstract

Neurofibromatosis type 2 (NF2) protein, also known as merlin or schwannomin, is a tumor suppressor, and NF2 is mutated in most schwannomas and meningiomas. Although these tumors are dependent on NF2, some lack detectable NF2 mutations, which indicates that alternative mechanisms exist for inactivating merlin. Here, we demonstrate cleavage of merlin by the ubiquitous protease calpain and considerable activation of the calpain system resulting in the loss of merlin expression in these tumors. Increased proteolysis of merlin by calpain in some schwannomas and meningiomas exemplifies tumorigenesis linked to the calpain-mediated proteolytic pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701243     DOI: 10.1038/nm0898-915

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  29 in total

1.  Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2.

Authors:  Hyo Sang Jang; Sangeet Lal; Jeffrey A Greenwood
Journal:  Neurochem Res       Date:  2010-08-21       Impact factor: 3.996

2.  Augmented generation of protein fragments during wakefulness as the molecular cause of sleep: a hypothesis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2012-11       Impact factor: 6.725

3.  Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein.

Authors:  K Liu; L Li; P E Nisson; C Gruber; J Jessee; S N Cohen
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.

Authors:  David M Gau; Jamie L Lesnock; Brian L Hood; Rohit Bhargava; Mai Sun; Kathleen Darcy; Soumya Luthra; Uma Chandran; Thomas P Conrads; Robert P Edwards; Joseph L Kelley; Thomas C Krivak; Partha Roy
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases.

Authors:  J Lasota; J F Fetsch; A Wozniak; B Wasag; R Sciot; M Miettinen
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

6.  NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Authors:  Maria E R Garcia-Rendueles; Julio C Ricarte-Filho; Brian R Untch; Iňigo Landa; Jeffrey A Knauf; Francesca Voza; Vicki E Smith; Ian Ganly; Barry S Taylor; Yogindra Persaud; Gisele Oler; Yuqiang Fang; Suresh C Jhanwar; Agnes Viale; Adriana Heguy; Kety H Huberman; Filippo Giancotti; Ronald Ghossein; James A Fagin
Journal:  Cancer Discov       Date:  2015-09-10       Impact factor: 39.397

7.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Post-translational control of Myc function during differentiation.

Authors:  Maralice Conacci-Sorrell; Robert N Eisenman
Journal:  Cell Cycle       Date:  2011-02-15       Impact factor: 4.534

9.  Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains.

Authors:  G W Neill; M R Crompton
Journal:  Biochem J       Date:  2001-09-15       Impact factor: 3.857

10.  Alveolar echinococcosis: characterization of diagnostic antigen Em18 and serological evaluation of recombinant Em18.

Authors:  Yasuhito Sako; Minoru Nakao; Kazuhiro Nakaya; Hiroshi Yamasaki; Bruno Gottstein; Marshall W Lightowers; Peter M Schantz; Akira Ito
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.